Jen‐Chung Ko

1.8k total citations
66 papers, 1.3k citations indexed

About

Jen‐Chung Ko is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Jen‐Chung Ko has authored 66 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 28 papers in Pulmonary and Respiratory Medicine and 25 papers in Oncology. Recurrent topics in Jen‐Chung Ko's work include Lung Cancer Treatments and Mutations (16 papers), DNA Repair Mechanisms (9 papers) and Cancer therapeutics and mechanisms (9 papers). Jen‐Chung Ko is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), DNA Repair Mechanisms (9 papers) and Cancer therapeutics and mechanisms (9 papers). Jen‐Chung Ko collaborates with scholars based in Taiwan, United States and Japan. Jen‐Chung Ko's co-authors include Yun‐Wei Lin, Meng‐Rui Lee, Sheng‐Kai Liang, Shih‐Ci Ciou, Chong‐Jen Yu, Chao‐Min Cheng, Szu‐Ting Lin, Jin‐Yuan Shih, Jann‐Yuan Wang and Ying-Jhen Su and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Cancer Research.

In The Last Decade

Jen‐Chung Ko

65 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jen‐Chung Ko Taiwan 22 554 358 327 201 163 66 1.3k
Likun Gong China 24 541 1.0× 285 0.8× 139 0.4× 122 0.6× 66 0.4× 89 1.5k
Liang Ren China 18 678 1.2× 252 0.7× 202 0.6× 109 0.5× 595 3.7× 67 2.0k
Leo Stolk Netherlands 23 468 0.8× 249 0.7× 128 0.4× 202 1.0× 216 1.3× 68 2.4k
M. J. X. Hillebrand Netherlands 31 769 1.4× 812 2.3× 253 0.8× 186 0.9× 288 1.8× 77 2.6k
Fusao Komada Japan 21 391 0.7× 309 0.9× 204 0.6× 89 0.4× 68 0.4× 67 1.3k
Ryoko Yumoto Japan 25 654 1.2× 887 2.5× 386 1.2× 108 0.5× 112 0.7× 96 2.3k
Nitin Mehrotra United States 22 360 0.6× 395 1.1× 182 0.6× 130 0.6× 256 1.6× 59 1.8k
Bin Zhao China 23 388 0.7× 301 0.8× 189 0.6× 154 0.8× 101 0.6× 97 1.5k
Robert S. Jansen Netherlands 25 859 1.6× 548 1.5× 124 0.4× 261 1.3× 323 2.0× 64 2.1k

Countries citing papers authored by Jen‐Chung Ko

Since Specialization
Citations

This map shows the geographic impact of Jen‐Chung Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jen‐Chung Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jen‐Chung Ko more than expected).

Fields of papers citing papers by Jen‐Chung Ko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jen‐Chung Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jen‐Chung Ko. The network helps show where Jen‐Chung Ko may publish in the future.

Co-authorship network of co-authors of Jen‐Chung Ko

This figure shows the co-authorship network connecting the top 25 collaborators of Jen‐Chung Ko. A scholar is included among the top collaborators of Jen‐Chung Ko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jen‐Chung Ko. Jen‐Chung Ko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liang, Sheng‐Kai, Li‐Ta Keng, Meng‐Rui Lee, et al.. (2023). Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients. Cancer Medicine. 12(17). 17993–18004. 3 indexed citations
2.
3.
Chang, Chia‐Hao, Lih‐Yu Chang, Jen‐Chung Ko, et al.. (2023). Incidence of and Risk Factors for Acute Kidney Injury During Antituberculosis Treatment: A Prospective Cohort Study and Literature Review. Infectious Diseases and Therapy. 12(3). 919–931. 7 indexed citations
4.
Kuo, Lu-Cheng, Po‐Chih Kuo, Meng‐Rui Lee, et al.. (2023). A deep learning model using chest X-ray for identifying TB and NTM-LD patients: a cross-sectional study. Insights into Imaging. 14(1). 67–67. 17 indexed citations
5.
Kuo, Chih‐Hsi S., Po‐Lan Su, Yu‐Feng Wei, et al.. (2023). T790M detection rate after first-line combination therapy with bevacizumab and EGFR-TKIs in advanced NSCLC (TERRA Study). PubMed Central. 3 indexed citations
6.
Liang, Sheng‐Kai, Yueh‐Feng Wen, Chia‐Hao Chang, et al.. (2021). Exploring Volatile Organic Compounds in Breath for High-Accuracy Prediction of Lung Cancer. Cancers. 13(6). 1431–1431. 74 indexed citations
7.
8.
Hsiao, Shih-Hsin, et al.. (2020). Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR–TKI Tolerance and Lung Cancer Dissemination. Cancer Research. 80(20). 4426–4438. 43 indexed citations
9.
Lee, Meng‐Rui, Kai‐Lun Yu, Tsung‐Hao Liu, et al.. (2019). Outcome of stage IV cancer patients receiving in-hospital cardiopulmonary resuscitation: a population-based cohort study. Scientific Reports. 9(1). 9478–9478. 16 indexed citations
10.
Pan, Chun‐Hao, et al.. (2016). Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. BMC Cancer. 16(1). 857–857. 52 indexed citations
11.
Ko, Jen‐Chung, Po‐Yuan Chang, Jyh‐Cheng Chen, et al.. (2015). Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells. Biochemical Pharmacology. 97(3). 331–340. 8 indexed citations
12.
13.
Ko, Jen‐Chung, Yu‐Ching Huang, Shao‐Hsing Weng, et al.. (2012). HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells. Regulatory Toxicology and Pharmacology. 64(3). 415–424. 20 indexed citations
14.
Ko, Jen‐Chung, Shih‐Ci Ciou, Chao‐Min Cheng, et al.. (2009). Roles of MKK1/2-ERK1/2 and Phosphoinositide 3-Kinase–AKT Signaling Pathways in Erlotinib-Induced Rad51 Suppression and Cytotoxicity in Human Non–Small Cell Lung Cancer Cells. Molecular Cancer Research. 7(8). 1378–1389. 38 indexed citations
15.
Chen, Ruey-Shyang, Ying-Jhen Su, Wei‐Ting Lee, et al.. (2009). Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. Experimental Cell Research. 315(15). 2658–2672. 26 indexed citations
16.
Ko, Jen‐Chung, Ying-Jhen Su, Szu‐Ting Lin, et al.. (2009). Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochemical Pharmacology. 79(4). 655–664. 63 indexed citations
17.
Ko, Jen‐Chung, et al.. (2008). Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Molecular Cancer Therapeutics. 7(11). 3632–3641. 35 indexed citations
18.
19.
Ko, Jen‐Chung, Pan‐Chyr Yang, Ang Yuan, et al.. (1994). Superior vena cava syndrome : rapid histologic diagnosis by ultrasound-guided transthoracic needle aspiration biopsy. American Review of Respiratory Disease. 149(3). 783–787. 8 indexed citations
20.
Ko, Jen‐Chung, Pan‐Chyr Yang, Ang Yuan, et al.. (1994). Superior Vena Cava Syndrome. Rapid Histologic Diagnosis By Ultrasound-Guided Transthoracic Needle Aspiration Biopsy. American Journal of Respiratory and Critical Care Medicine. 149(3). 783–787. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Likun Gong Breakdown of academic impact, for papers by Liang Ren Breakdown of academic impact, for papers by Leo Stolk Breakdown of academic impact, for papers by M. J. X. Hillebrand Breakdown of academic impact, for papers by Fusao Komada Breakdown of academic impact, for papers by Ryoko Yumoto Breakdown of academic impact, for papers by Nitin Mehrotra Breakdown of academic impact, for papers by Bin Zhao Breakdown of academic impact, for papers by Robert S. Jansen
Rankless by CCL
2026